Key indicators: single-crystal X-ray study; T = 110 K; mean (C-C) = 0.003 Å; R factor = 0.071; wR factor = 0.129; data-to-parameter ratio = 15.6. There are also C-HÁ Á ÁO hydrogen bonds involving the nitrofurantoin molecules which support the key hydrogenbonding synthon. The overall crystal packing is further assisted by weak C-HÁ Á ÁO interactions, giving a herringbone pattern. 
The antibiotic nitrofurantoin {systematic name: (E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione} crystallizes as a methanol monosolvate, C 8 H 6 N 4 O 5 ÁCH 4 O. The nitrofurantoin molecule adopts a nearly planar conformation (r.m.s. deviation = 0.0344 Å ). Hydrogen bonds involve the cooperative N-HÁ Á ÁO-HÁ Á ÁO heterosynthons between the cyclic imide of nitrofurantoin and methanol O-H groups. There are also C-HÁ Á ÁO hydrogen bonds involving the nitrofurantoin molecules which support the key hydrogenbonding synthon. The overall crystal packing is further assisted by weak C-HÁ Á ÁO interactions, giving a herringbone pattern.
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For polymorphism and pseudopolymorphs, see: Bernstein (2002) ; Byrn et al. (1999) ; Aitipamula et al. (2010) . For nitrofurantoin hydrate and anhydrate crystal structures, see: Otsuka et al. (1991) ; Pienaar et al. (1993a,b) ; Bertolasi et al. (1993) and for nitrofurantoin pseudopolymorphs, see : Caira et al. (1996) ; Tutughamiarso et al. (2011) . For a 1:1 co-crystal involving nitrofurantoin and 4-hydroxybenzoic acid, see: Vangala et al. (2011) . For hydrogen bonding, see: Desiraju & Steiner (1999) ; Desiraju (2002 Desiraju ( , 2007 Table 1 Hydrogen-bond geometry (Å , ). 
Comment
Polymorphism is an ability of a molecule to exist in two or more crystal structures. Incorporation of solvent molecules into the crystalline lattice are routinely referred to as solvates, inclusion complexes and/or pseudopolymorphs (Bernstein, 2002; Byrn et al., 1999; Aitipamula et al., 2010) . A full characterization of various crystal forms of an active pharmaceutical ingredient (API) may reveal desired physical form. Thus, it is relevant to pharmaceutical industry. Nitrofurantoin {(E)-1-
-dione} is an antibacterial agent used in the treatment of genitourinary tract infections. It exists in both anhydrous (α-and β-) and hydrate forms (Forms I and II) (Pienaar et al., 1993a (Pienaar et al., , 1993b Bertolasi et al., 1993) , and literature findings show that nitrofurantoin has poor physical properties (Otsuka et al., 1991; Caira et al., 1996) . We have recently reported a 1:1 co-crystal involving nitrofurantoin and 4-hydroxybenzoic acid and shown that co-crystal displayed superior physicochemical and photo-stability to that of nitrofurantoin. However, co-crystallization attempt of nitrofurantoin with fumaric acid in methanol instead yielded the title pseudopolymorph, nitrofurantoin methanol monosolvate. It was reported that this API is known to form inclusion complexes with dimethylformamide, dimethyl sulfoxide and dimethylacetamide (Caira et al., 1996; Tutughamiarso et al., 2011) . Herein we report the structural features of a 1:1 pseudopolymorph involving nitrofurantoin and methanol (Fig. 1 ).
Thermogravimetric analysis (TGA traces) of the title compound is shown in Fig. 2 . The measured weight loss (11.6% w/w) in the temperature range of 110-140 °C is in agreement with the stoichiometric weight content for a methanol monosolvate (11.8% w/w).
Single crystal X-ray diffraction analysis reveals that the crystal structure contains one molecule each of nitrofurantoin and methanol in the asymmetric unit (Fig. 1) . It has crystallized in the monoclinic crystal system with P2 1 /c space group.
In the structure, nitrofurantoin and methanol molecules were essentially held together by a primary co-operative synthon of N-H···O-H···O [D/Å, θ/°: 2.755 (2), 170 (3); 2.787 (2), 172 (3)] between amide N4-H4, methanolic O6-H6 and imide O5 along the a-axis (Fig. 3 ). In addition, there are significant C-H···O hydrogen bonds (Desiraju & Steiner 1999; Desiraju 2002; Desiraju 2007) within nitrofurantoin molecules, which lead to ribbons running along a-axis and support the key hydrogen bonding synthon (Fig. 4) . It has structural reminiscences with anhydrous nitrofurantoin (β-form), where the packing is stabilized by imide catemer of N-H···O interactions (Pienaar et al., 1993b; Bertolasi et al., 1993) . Here, however, it is replaced with N-H···O-H···O catemer type of heterosynthon by retaining a two fold screw axis. Recently, we have noted an identical synthon in a 1:1 co-crystal involving nitrofurantoin and phenolic co-former (4-hydroxybenzoic acid) (Vangala et al., 2011) . Hence, supramolecularly methnolic O-H interacted similar to what phenolic O-H is able to do in the reported co-crystal. The overall crystal packing of the title pseudopolymorph is further assisted by weak C-H···O interactions to
give a herringbone type of pattern (Fig. 5) . Further analysis showed that this herringbone pattern was comparable to that of a crystal structure of nitrofurantoin dimethyl sulfoxide monosolvate (Tutughamiarso et al., 2011) .
supplementary materials sup-2 Experimental
The title psuedopolymorph was obtained by evaporative crystallization during attempts to co-crystallize a commercially available (purchased from Aldrich) nitrofurantoin (β-form, 119 mg, 0.5 mmol) with fumaric acid (58 mg, 0.5 mmol) in methanol (25 ml) at ambient conditions. The yellow needle shaped crystals suitable for single-crystal X-ray diffraction were obtained in three days.
Refinement
All H atoms bonded to C, N, O atoms were located in a difference map and allowed to ride on their parent atoms in the refinement cycles. Figures   Fig. 1 . A perspective view showing the molecular structures of nitrofurantoin and methanol, with atom labels and 50% probability displacement ellipsoids for non-H atoms. The dashed line shows the N-H···O hydrogen bond. Fig. 2 . TGA traces showed that there was a weight loss of 11.6% (w/w), which can be attributed to a methanol solvate. 
